Cite
HARVARD Citation
Lum, L. et al. (2021). Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer. Journal for immunotherapy of cancer. 9 (6), p. . [Online].